①Jia Liang Brain Science completed a Series D financing, with investors including Sai Zhi Bole Investment, etc. The company has established three technology platforms for brain-computer control. ②The Ministry of Industry and Information Technology sought opinions on the guidelines for the brain-computer interface standard system. Zhejiang announced measures for industry-university-research collaboration, and products like Borui Kang have made progress.
Hangzhou Jialiang Brain Science completed its D-round financing, with investors being Saizhi Bole Investment, Kuanqiao Hengsong, and Ningbo State-owned Assets. The company was established in 2020, with its headquarters located in Hangzhou, Zhejiang. It focuses on the industrialization of cutting-edge brain science and neurosurgery technologies, with a core team of over 120 people. The company has developed three technology platforms: brain-computer control, medical lasers, and brain-computer chips, providing innovative medical device solutions for various neurological diseases. During the same period, the Ministry of Industry and Information Technology publicly solicited opinions on the “National Brain-Computer Interface Industry Standard System Construction Guidelines (2026 Edition)” in August 2026, planning to revise or establish more than 40 standards by 2028; Zhejiang Province issued measures for industry-university-research collaboration, encouraging companies to set prices independently and opening a “green channel” for the listing of medical consumables. In the same field, Boruikeong submitted an IPO application in June 2026, and its NEO-ONE SCI system was approved for marketing by the National Medical Products Administration and included in the Shanghai medical insurance catalog.